MaxCyte, Inc. Publication of Annual Report & Notification of AGM (8995A)
June 10 2016 - 9:04AM
UK Regulatory
TIDMMXCT
RNS Number : 8995A
MaxCyte, Inc.
10 June 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Publication of Annual Report and Notification of AGM
Maryland, USA - 10 June 2016: MaxCyte (LSE: MXCT), the developer
and supplier of cell engineering technology to biotechnology and
pharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology,
gives notice that its Annual Report and Accounts for the year ended
31 December 2015 ("Annual Report") has been published on the
"Investors" section of the Company's website at
www.maxcyte.com.
MaxCyte announced preliminary results for the year ended 31
December 2015 on 10 May 2016, and expects to post printed copies of
the Annual Report to stockholders in the Company ("Stockholders")
shortly.
Further copies of the Annual Report will be available from the
Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110,
Gaithersburg, MD 20878, USA.
MaxCyte also announces that its Annual General Meeting of
Stockholders is planned to be held on 26 October 2016 at 22
Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA. Formal
notice and resolutions, along with the Annual Meeting Proxy Card,
will be circulated on or about 1 September 2016 to Stockholders of
record on or about that date.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering technology to
biotechnology and pharmaceutical firms engaged in cell therapy,
drug discovery and development, biomanufacturing, gene editing and
immuno-oncology. The Company's patented flow electroporation
technology enables its products to deliver fast, reliable and
scalable cell engineering to drive the research and clinical
development of a new generation of cell-based medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, commercial
and clinical grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers with an established regulatory path.
MaxCyte is developing CARMA, its proprietary platform in
immuno-oncology, to deliver a validated non-viral approach to CAR
therapies in a number of cancer indications, including solid
tumors.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFEFDSFMSESM
(END) Dow Jones Newswires
June 10, 2016 09:04 ET (13:04 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024